NCT02862613

Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer

Clinical Study Using Precision Cell Immunotherapy Combined With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Shanghai International Medical Center · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Objectives: To evaluate the safety and effectiveness of cell therapy using Precision Cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Liver Cancer.

Detailed description

A total of 40 patients may be enrolled over a period of 1-2 years.

Conditions

• Precision Cells
• Transcatheter Arterial Chemoembolization
• Advanced Liver Cancer

Interventions

Type	Name	Description
PROCEDURE	TACE	Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
BIOLOGICAL	Precision Cells	DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.

Timeline

• Start date: 2016-08-01
• Primary completion: 2018-03-01
• Completion: 2018-08-01
• First posted: 2016-08-11
• Last updated: 2016-09-02

Locations

1 site across 1 country: China